Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03014063
Recruitment Status : Completed
First Posted : January 9, 2017
Last Update Posted : January 31, 2019
Sponsor:
Information provided by (Responsible Party):
The Cleveland Clinic

Brief Summary:
This is a prospective observational cohort trial evaluating a single plasma vasopressin concentration in patients receiving exogenous, adjunctive vasopressin for septic shock. The trial is designed to determine whether plasma vasopressin concentration influences the likelihood of hemodynamic response to exogenous vasopressin therapy.

Condition or disease
Septic Shock

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 18 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Vasopressin Plasma Concentrations in Responders and Non-responders to Exogenous Vasopressin Infusion in Patients With Septic Shock
Study Start Date : November 2016
Actual Primary Completion Date : June 2017
Actual Study Completion Date : June 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock

Group/Cohort
Hemodynamic responders
Those with a mean arterial pressure of at least 65mmHg and a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
Hemodynamic non-responders
Those without a mean arterial pressure of at least 65mmHg and/or a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration



Primary Outcome Measures :
  1. Plasma vasopressin concentration [ Time Frame: 3-6 hours from initiation of exogenous vasopressin administration ]

Secondary Outcome Measures :
  1. Mean arterial pressure [ Time Frame: Analyzed at time of vasopressin blood draw, 3-6 hours from initiation of exogenous vasopressin administration ]
  2. Catecholamine dose in norepinephrine equivalents [ Time Frame: Analyzed at time of vasopressin blood draw, 3-6 hours from initiation of exogenous vasopressin administration ]
  3. ICU mortality [ Time Frame: Analyzed at ICU discharge, up to 1 year ]
  4. In-hospital mortality [ Time Frame: Analyzed at hospital discharge, up to 1 year ]
  5. Vasopressor-free days [ Time Frame: Day 14 ]
  6. ICU-free days [ Time Frame: Day 14 ]
  7. Acute kidney injury [ Time Frame: Analyzed at ICU discharge, up to 1 year ]

Biospecimen Retention:   Samples Without DNA
Plasma vasopressin concentration in patients receiving exogenous vasopressin


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with septic shock that are receiving fixed-dose exogenous vasopressin as an adjunct to catecholamines
Criteria

Inclusion Criteria:

  • Patients with septic shock as defined by The Third International Consensus Definitions for Sepsis and Septic Shock
  • Patients ≥18 years of age
  • Treatment with exogenous vasopressin, as ordered by the primary medical team, at a constant infusion rate for at least 3 hours as an adjunctive vasopressor to catecholamine therapy
  • Admission to a medical, surgical, or neurosciences intensive care unit
  • Presence of a central venous catheter or arterial line (as determined by the primary medical team)

Exclusion Criteria:

  • Patients treated with vasopressin for indications other than septic shock
  • Patients administered vasopressin that is titrated within the first 3 hours
  • Patients receiving vasopressin as the sole vasoactive therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03014063


Locations
Layout table for location information
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
The Cleveland Clinic
Publications:
Sacha G, Torbic H, Lam S, Bass S, Harinstein L, Welch S, Duggal A, Bauer S. 1355: Predictors of Response to Fixed-Dose Vasopressin in Adult Patients with Septic Shock. Crit Care Med. 2016 Dec;44(12 Suppl 1):414.

Layout table for additonal information
Responsible Party: The Cleveland Clinic
ClinicalTrials.gov Identifier: NCT03014063    
Other Study ID Numbers: 16-1254
First Posted: January 9, 2017    Key Record Dates
Last Update Posted: January 31, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by The Cleveland Clinic:
sepsis
septic shock
vasopressin
AVP
Additional relevant MeSH terms:
Layout table for MeSH terms
Shock, Septic
Shock
Pathologic Processes
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation